CA2638807A1 - Lymphatic zip codes in tumors and pre-malignant lesions - Google Patents

Lymphatic zip codes in tumors and pre-malignant lesions Download PDF

Info

Publication number
CA2638807A1
CA2638807A1 CA002638807A CA2638807A CA2638807A1 CA 2638807 A1 CA2638807 A1 CA 2638807A1 CA 002638807 A CA002638807 A CA 002638807A CA 2638807 A CA2638807 A CA 2638807A CA 2638807 A1 CA2638807 A1 CA 2638807A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
conservative amino
acid substitutions
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002638807A
Other languages
English (en)
French (fr)
Inventor
Erkki Ruoslahti
Lianglin Zhang
Douglas Hanahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
University of California San Diego UCSD
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2638807A1 publication Critical patent/CA2638807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
CA002638807A 2006-02-01 2007-02-01 Lymphatic zip codes in tumors and pre-malignant lesions Abandoned CA2638807A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76417506P 2006-02-01 2006-02-01
US60/764,175 2006-02-01
PCT/US2007/061480 WO2007090194A2 (en) 2006-02-01 2007-02-01 Lymphatic zip codes in tumors and pre-malignant lesions

Publications (1)

Publication Number Publication Date
CA2638807A1 true CA2638807A1 (en) 2007-08-09

Family

ID=38328164

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002638807A Abandoned CA2638807A1 (en) 2006-02-01 2007-02-01 Lymphatic zip codes in tumors and pre-malignant lesions

Country Status (5)

Country Link
US (3) US7919466B2 (https=)
EP (1) EP1996607A4 (https=)
JP (1) JP2009525055A (https=)
CA (1) CA2638807A1 (https=)
WO (1) WO2007090194A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996607A4 (en) 2006-02-01 2009-06-24 Burnham Inst Medical Research LYMPH ADDRESS CODES FOR TUMORS AND PREMALARY LESIONS
FI121959B (fi) 2008-05-09 2011-06-30 Pirjo Laakkonen Aivokasvaimiin hakeutuva peptidi
TW201004658A (en) * 2008-07-31 2010-02-01 Enzon Pharmaceuticals Inc Nanoparticle compositions for nucleic acids delivery system
TW201021852A (en) * 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable fusogenic lipids for nucleic acids delivery systems
TW201021853A (en) * 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable cationic lipids for nucleic acids delivery systems
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
WO2011127405A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
AU2012262488A1 (en) 2011-05-31 2014-01-16 Airware, Inc. Re-calibration of AB NDIR gas sensors
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
GB201710097D0 (en) * 2017-06-23 2017-08-09 Univ Ulster A sensitizer - peptide conjugate
WO2023064887A1 (en) 2021-10-15 2023-04-20 The Board Of Trustees Of The University Of Illinois Mechanochemical dynamic therapy for focal cancer treatment
WO2024115720A1 (en) * 2022-12-01 2024-06-06 Hairvel Oü Novel peptide conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156581T5 (es) * 1998-03-30 2015-01-21 Northwest Biotherapeutics, Inc. Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1383883A2 (en) * 2001-04-24 2004-01-28 Isis Innovation Limited Asthma-associated snps around microsatellite marker d2s308 and identification of human prolyl-oligopeptidase-dpp10
EP1581790B1 (en) 2001-11-08 2009-01-07 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
US7723474B2 (en) 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
EP1996607A4 (en) 2006-02-01 2009-06-24 Burnham Inst Medical Research LYMPH ADDRESS CODES FOR TUMORS AND PREMALARY LESIONS

Also Published As

Publication number Publication date
WO2007090194A3 (en) 2008-07-10
US8536132B2 (en) 2013-09-17
EP1996607A2 (en) 2008-12-03
JP2009525055A (ja) 2009-07-09
US20070219134A1 (en) 2007-09-20
US20110212162A1 (en) 2011-09-01
WO2007090194A2 (en) 2007-08-09
US8951971B2 (en) 2015-02-10
US7919466B2 (en) 2011-04-05
US20140220106A1 (en) 2014-08-07
EP1996607A4 (en) 2009-06-24

Similar Documents

Publication Publication Date Title
US7919466B2 (en) Lymphatic zip codes in tumors and pre-malignant lesions
ES2334118T3 (es) Agentes de union especifica de la angiopoyetina-2.
US8835605B2 (en) Uses of cancer-targeting peptides in cancer diagnosis
KR20090102744A (ko) 방사선요법 및 화학요법에 대하여 암세포를 민감하게 하기 위한 표적화 엔비에스1―에이티엠 상호작용
US6632616B2 (en) Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
JP2010508305A (ja) スムースンドポリペプチドおよび使用方法
KR20170073611A (ko) Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
WO2011020107A2 (en) Compositions and methods for detection and treatment of breast cancer
BRPI0919777B1 (pt) Derivados de peptídeo e uso dos mesmos como vetores para moléculas na forma de conjugados
AU2017234528B2 (en) Neutralizing monoclonal antibodies to IL-25 and uses thereof
US8258256B2 (en) Compositions and methods for the treatment of cancer
CN102105487A (zh) 靶向crkl的肽
BR112013024265B1 (pt) peptídeos cíclicos, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica
WO2009067520A2 (en) Peptides specific for hepatocellular carcinoma cells and applications thereof
US11407788B2 (en) Prostate-specific membrane antigen (PSMA) targeting peptides
CA2634934A1 (en) Endometriosis cell targeting peptide and uses thereof
US12264184B2 (en) DAP12 constructs and their use to enhance DC vaccines and immunotherapies
US20240293460A1 (en) Dkk1/hla-a2 binding molecules and methods of their use
WO2017019454A2 (en) Identification of novel anti-fibrotic peptide in c-terminal region of the met receptor tyrosine kinase
Cupka Development of an αᵥβ₆-Binding Peptide for In Vivo Applications: Modulation of Serum Stability and Biodistribution
BRPI0216042B1 (pt) Polipeptídeo capaz de se ligar a ANG-2, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso dos referidos polipeptídeos.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130201